Prime editing of human hematopoietic stem cells for correction of GATA2 deficiency.

Prime editing achieves up to 70% correction of GATA2 variants in human CD34+ hematopoietic stem cells, increasing functional GATA2 alleles from 50 to 77%.

• Why it matters: GATA2 deficiency causes severe immunodeficiency, and current gene editing methods face challenges like off-target effects and reduced cell engraftment, limiting therapeutic potential.
• What they did: The study developed a prime editing approach to correct GATA2 mutations in patient-derived CD34+ HSPCs, demonstrating efficient editing, increased engraftment potential, and limited genotoxicity at top predicted off-target sites.
• The result: This preclinical work suggests prime editing can provide a safe, effective, and broadly applicable gene therapy for GATA2 deficiency, supporting further development toward clinical application.